Flush-Free Niacin 500 mg

Flush-Free Niacin 500 mg

Bluebonnet4.7 (118 ratings)
Format:Capsule Quantity: 120 Capsule(s) · 120 servings
Goals
$30.80 $0.25 per serving

Product analysis

64 out of 100

Flush-Free Niacin 500 mg offers an explicitly identified niacin preparation, making it easier to distinguish from other forms. Its connection to cardiovascular support remains uncertain for this particular preparation.

AI assessment of the formula, label and price. How scoring works

Nutrient Quality70

The niacin preparation is clearly identified, avoiding ambiguity about which form is included. The inositol preparation is named, but its quality cannot be confirmed.

Ingredient Transparency100

Amounts and preparations are disclosed for both listed ingredients. That makes it easier to compare the contents with other niacin supplements.

Value For Money60

The identified niacin preparation offers moderate value for the serving cost. The added inositol does not establish a further value advantage.

Customer Satisfaction72

Customer feedback is very positive, though based on a relatively small pool of ratings. That limits confidence about how widely satisfaction is shared.

Product Focus0

A cardiovascular benefit cannot be established for this inositol-bound niacin preparation. That uncertainty does not prove ineffectiveness, but it limits the basis for choosing it for that purpose.

Format
Capsule
Container
120 Capsule(s)
Per serving
$0.25
Customer rating
4.7 · 118 ratings
Report analysis

Goals

Heart Health
Impact
Limited evidence
F Ingredient FitF PathwaysF EvidenceF Formulation Logic
Study evidence
Niacin Supportive 105 studies
Cardiovascular Support
Impact
Limited evidence
F Ingredient FitF PathwaysF EvidenceF Formulation Logic
Niacin · 500 mg
Study evidence
Niacin Supportive 136 studies

Ingredients

IngredientAmount per servingScore
Niacin (Inositol Hexaniacinate)
500 mg 68
Inositol (Inositol Hexanicotinate)
88 mg
Gluten Free Adults 18–50 Vegan Kosher Dairy Free Sugar Free No Allergies Vegetarian
Report overview
C Active Ingredient Quality & BioavailabilityB Dose, Safety & Label TransparencyC Value
Each serving provides 500 mg of niacin. The price per serving is moderate for the niacin form. It uses inositol hexanicotinate, a non-flushing niacin form.
How this ingredient is rated

Active Ingredient Quality & Bioavailability64

It uses inositol hexanicotinate, a non-flushing niacin form.
Niacin Form & Goal Alignment
It uses inositol hexanicotinate, a non-flushing niacin form.
Precursor Source Quality
The source is inositol hexanicotinate.

Dose, Safety & Label Transparency75

Each serving provides 500 mg of niacin. The label describes inositol hexanicotinate as flush-free.
Clarity of Chemical Form
The label names inositol hexanicotinate.
Form-Specific Dosage Efficacy
Each serving provides 500 mg of niacin.
Flush Risk & Safety Labeling
The label describes inositol hexanicotinate as flush-free.

Value60

The price per serving is moderate for the niacin form.
Price Per Effective Serving
The price per serving is moderate for the niacin form.
Report alternatives

Sources

Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.

  1. The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression.
    Lavigne PM; Karas RH · Journal of the American College of Cardiology · 2013
    Meta-analysis9,959 participants11 studies pooledCardiovascular Support forNiacin
  2. Effects of niacin on apo A1 and B levels: a systematic review and meta-analysis of randomised controlled trials.
    Saboori S; Yousefi Rad E; Tammam J; Thondre PS; Coe S · The British journal of nutrition · 2024
    Meta-analysis12 studies pooledCardiovascular Support forNiacin
  3. Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials.
    Xie S; Galimberti F; Olmastroni E; Carugo S; Catapano AL; Casula M; META-LIPID Group · Atherosclerosis · 2025
    Meta-analysis145,314 participants147 studies pooledCardiovascular Support forNiacin
  4. Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.
    Guyton JR; Blazing MA; Hagar J; Kashyap ML; Knopp RH; McKenney JM; Nash DT; Nash SD · Archives of internal medicine · 2000
    Randomized trial173 participantsCardiovascular Support forNiacin
  5. Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia.
    Knopp RH; Alagona P; Davidson M; Goldberg AC; Kafonek SD; Kashyap M; Sprecher D; Superko HR; Jenkins S; Marcovina S · Metabolism: clinical and experimental · 1998
    Randomized trial223 participantsCardiovascular Support forNiacin
  6. Differential effect of two nicotinic acid preparations on low-density lipoprotein subclass distribution in patients classified as low-density lipoprotein pattern A, B, or I.
    Superko HR; McGovern ME; Raul E; Garrett B · The American journal of cardiology · 2004
    Randomized trial180 participantsHeart Health forNiacin
  7. The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration.
    Villines TC; Stanek EJ; Devine PJ; Turco M; Miller M; Weissman NJ; Griffen L; Taylor AJ · Journal of the American College of Cardiology · 2010
    Randomized trial315 participantsHeart Health forNiacin
  8. The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome.
    Thoenes M; Oguchi A; Nagamia S; Vaccari CS; Hammoud R; Umpierrez GE; Khan BV · International journal of clinical practice · 2008
    Randomized trial50 participantsHeart Health forNiacin
  9. Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease.
    Duggal JK; Singh M; Attri N; Singh PP; Ahmed N; Pahwa S; Molnar J; Singh S; Khosla S; Arora R · Journal of cardiovascular pharmacology and therapeutics · 2010
    Meta-analysis5,137 participants7 studies pooledHeart Health forNiacin
  10. Effect of niacin on endothelial function: a systematic review and meta-analysis of randomized controlled trials.
    Sahebkar A · Vascular medicine (London, England) · 2014
    Meta-analysis441 participants7 studies pooledHeart Health forNiacin